Bio-Rad Releases Poster That Describes Transfection
Of Primary and Difficult-to-Transfect Cells
HERCULES,
Calif., April 1, 2008 – Bio-Rad
Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and
distributor of life science research and clinical diagnostic products, announced
today the availability of a poster (number 07-0883) that was displayed at the
Association for Biomolecular Resource Facilities Annual Meeting held in
February, 2008.
In the poster, Bio-Rad demonstrates how high efficiency
electroporation of several difficult-to-transfect cell lines was achieved using
the parameter optimization capabilities of the Gene Pulser MXcell™
electroporation system. Electroporation conditions, including optimal waveform
and pulse conditions, were determined in parallel for each cell type. Results of
several difficult-to-transfect cell types, including HUVEC (human umbilical
vein endothelial cell), Jurkat, and mouse neuroblastoma cells (Neuro-2A) with
plasmid DNA or siRNA, are shown.
Data presented in the poster shows that four-hours post electroporation with a GAPDH siRNA, HUVEC cells expressed less than 97% of GAPDH mRNA than controls transfected with scrambled siRNA. In Jurkat cells, significant silencing was also obtained (>88%) as quickly as four hours post transfection and this silencing persisted for 48 hour. . Transfection of Neuro-2A cells with a fluorescently labeled siRNA followed by analysis with flow cytometry resulted in 75% transfection efficiency.
Availability
Poster 07-0883 is available either from a local Bio-Rad sales office or it may be downloaded from the Bio-Rad web site at www.bio-rad.com. For more information on optimization of electroporation parameters and conditions see Bio-Rad’s technical note 5622, which can also be downloaded online.
About Electroporation
Electroporation is a valuable tool for nucleic acid delivery because it can be used for a wide variety of cell types. Along with a general movement in the scientific community to use more medically relevant cells, new tools for electroporation have become necessary as more scientists optimize delivery of siRNA, plasmids, or other molecules into mammalian cells, in particular, primary cells and those cells that are difficult-to-transfect.
About
Bio-Rad
Bio-Rad
Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of
scientific discovery for more than 50 years manufacturing and distributing a
broad range of products for the life science research and clinical diagnostic
markets. The company is renowned worldwide among hospitals, universities, major
research institutions, as well as biotechnology and pharmaceutical companies
for its commitment to quality and customer service. Founded in 1952, Bio-Rad is
headquartered in Hercules, California, and serves more than 85,000 research and
industry customers worldwide through its global network of operations. The
company employs approximately 6,300 people globally and had revenues
approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
For more
information, please contact:
Jamie Wibbenmeyer
Bio-Rad Laboratories, Inc.
510-724-4770
Doug Forsyth
Alchymia Communications ® LLC
541-482-8744